Companies / BOC Sciences / Tildrakizumab
BOC Sciences

Tildrakizumab | BOC Sciences

(0) Write Review

Tildrakizumab is a monoclonal antibody used in the treatment of moderate to severe plaque psoriasis, a chronic autoimmune skin condition characterized by red, itchy, and scaly patches on the skin. Tildrakizumab targets and blocks interleukin-23 (IL-23), a cytokine involved in the inflammatory pathway that drives psoriasis. By inhibiting IL-23, tildrakizumab helps to reduce the inflammation and abnormal skin cell growth associated with psoriasis. It is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tildrakizumab is typically used in patients who have not responded adequately to other treatments or have experienced intolerable side effects.

Reviews

(0) | Be the first to review this product
No reviews yet

ABOUT THE COMPANY

BOC Sciences
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.
Scientific Products
  • See More
    • Upcoming Virtual Events
    Upcoming Webinars